TY  - JOUR
AU  - Polvere, Immacolata
AU  - Voccola, Serena
AU  - Cardinale, Gaetano
AU  - Fumi, Maurizio
AU  - Aquila, Francesca
AU  - Parrella, Alfredina
AU  - Madera, Jessica Raffaella
AU  - Stilo, Romania
AU  - Vito, Pasquale
AU  - Zotti, Tiziana
PY  - 2022
TI  - A peptide-based assay discriminates individual antibody response to SARS-CoV-2
JO  - Genes & Diseases
SN  - 2352-4820
SP  - 275
EP  - 281
VL  - 9
IS  - 1
AB  - SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines, therapeutics and public health interventions. However, lack of consistency in methods used to monitor antibody response to SARS-CoV-2 leaves some uncertainty in our fine understanding of the human antibody response mounted following SARS-CoV-2 infection. We developed a peptide-based enzyme-linked immunosorbent assay (ELISA) by selecting 7 synthetic peptides from the spike, membrane, and nucleocapsid protein sequences of SARS-CoV-2, which effectively detects the antibody response mounted by all COVID-19 convalescent tested. Strikingly, the assay shows a profound difference in antibody response among individual subjects, which may have a significant impact on disease severity. Together, our results define an efficient and specific serological assay to consistently measure the antibody response following SARS-CoV-2 infection, as well as help the design of vaccine and therapeuticals for prevention and treatment of COVID-19.
UR  - https://doi.org/10.1016/j.gendis.2021.01.008
DO  - 10.1016/j.gendis.2021.01.008